N-[4-([(2-Amino-4-oxo-1,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]{(2E)-3-[4-carbamoyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1H-imidazol-5-yl]-2-propenoyl}amino)benzoyl]-L-glutamic acid

DB04057ExperimentalSmall molecule

N-[4-([(2-Amino-4-oxo-1,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]{(2E)-3-[4-carbamoyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1H-imidazol-5-yl]-2-propenoyl}amino)benzoyl]-L-glutamic acid: Overview.

Formula / weight: C₃₂H₃₄N₉O₁₅P · 815.6374 g/mol (avg)
Also known as: beta-DADF, MSA, multisubstrate adduct inhibitor · β-DADF, MSA, multisubstrate adduct inhibitor

Resolves to

Compound

PubChem6323417

Structure

InChIKeyXRZABKCMPVBQFX-UGTLBTQMSA-NSMILES

[H]N([H])C(=O)C1=C(\C=C\C(=O)N(CC2=NC3=C(C=C2)N([H])C(=NC3=O)N([H])[H])C2=CC=C(C=C2)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)N(C=N1)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O

Targets

P31939ATIC

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with N-[4-([(2-Amino-4-oxo-1,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]{(2E)-3-[4-carbamoyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1H-imidazol-5-yl]-2-propenoyl}amino)benzoyl]-L-glutamic acid, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account